Investor Type | Firm |
Industries | PropTech • BioTech • FinTech (& Financials services) • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Real Estate (& Construction) • Healthcare (& Wellness) • Pharmaceutical (& Medicine) |
Stages | Seed, Series A, Series B |
Investing | United States • China |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $300,000,000 |
Pivotal bioVenture Partners is an investment firm founded by Vincent Cheung in 2017, with Pivotal bioVenture Partners China established in 2018. As a life sciences-oriented investor, they focus on several industries such as PropTech, BioTech, FinTech and Financial Services, HealthTech and Fitness, Medical Devices and Hospital Services, Real Estate and Construction, Healthcare and Wellness, as well as Pharmaceutical and Medicine. They provide investments for seed, Series A, and Series B stages of company development. With assets under management amounting to $300,000,000, Pivotal bioVenture Partners considers investments ranging from a minimum of $100,000 to a maximum of $5,000,000, with a 'sweet spot' investment size of about $1,500,000. Vincent Cheung, the firm's founder, also chairs Nan Fung Life Sciences and serves as the Managing Director and CEO of the Nan Fung Group. He has substantial financial sector experience, previously holding positions at Barclays Capital Asia Limited and Citigroup Global Markets Asia Limited. Additionally, Vincent is deeply involved in the life sciences community, as evidenced by his roles with the Hong Kong Life Sciences Society, the Hong Kong BioMedical Technology Development Advisory Panel, and as a board member of the Hong Kong University Technology Transfer Office. The firm operates with a strategic vision focused on nurturing young talent within the life sciences ecosystem in Hong Kong and has a physical presence in Shanghai, China.